MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Avanos Medical Cost of Revenue 2011-2026 | AVNS
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Avanos Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 347 M | 306 M | 294 M | 290 M | 379 M | 344 M | 295 M | 261 M | 275 M | 269 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 379 M | 261 M | 306 M |
Quarterly Cost of Revenue Avanos Medical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 91.8 M | 82.9 M | 77.7 M | - | 77.5 M | 76.1 M | 71.3 M | - | 75.8 M | 71.6 M | 67.9 M | - | 72.1 M | 69.3 M | 90.8 M | - | 93.9 M | 100 M | 90.4 M | - | 89.9 M | 77.2 M | 78.3 M | - | 76.4 M | 73.5 M | 65.4 M | - | 60.4 M | 66.2 M | 65.3 M | - | 69.5 M | 64.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 100 M | 60.4 M | 76.8 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alphatec Holdings
ATEC
|
232 M | $ 11.9 | -2.06 % | $ 1.79 B |  USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 4.29 | 2.39 % | $ 908 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
LivaNova PLC
LIVN
|
448 M | $ 62.99 | -0.4 % | $ 3.44 B |  Britain |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
LENSAR
LNSR
|
27.6 M | $ 5.72 | -5.85 % | $ 65.9 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
IRIDEX Corporation
IRIX
|
30.1 M | $ 1.35 | -0.22 % | $ 21.8 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Medtronic PLC
MDT
|
11.6 B | $ 87.15 | -0.07 % | $ 112 B | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
AxoGen
AXGN
|
57.9 M | $ 32.23 | 1.51 % | $ 1.48 B | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 36.47 | -0.44 % | $ 1.13 B | USA |
 |
Electromed
ELMD
|
14 M | $ 24.44 | -0.2 % | $ 207 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Cytosorbents Corporation
CTSO
|
10.5 M | $ 0.68 | 0.86 % | $ 37 M | USA |
 |
Aethlon Medical
AEMD
|
3.87 M | $ 2.24 | -2.61 % | $ 3.5 M | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Orthofix Medical
OFIX
|
256 M | $ 11.9 | 0.25 % | $ 471 M |  Curacao |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 11.04 | 6.41 % | $ 1.49 B | USA |
 |
Myomo
MYO
|
14 M | $ 0.72 | 2.1 % | $ 30.1 M | USA |
 |
IRadimed Corporation
IRMD
|
19.5 M | $ 99.94 | 0.75 % | $ 1.27 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
21.9 M | $ 2.36 | -3.28 % | $ 138 M |  Israel |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.85 | 3.08 % | $ 144 M |  France |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 16.26 | -1.28 % | $ 381 M | USA |
 |
Penumbra
PEN
|
461 M | $ 335.06 | -0.15 % | $ 13 B | USA |
 |
Outset Medical
OM
|
72.7 M | $ 3.51 | -3.04 % | $ 53.4 K | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 51.85 | -0.69 % | $ 1.52 B | USA |
 |
Insulet Corporation
PODD
|
768 M | $ 225.55 | -0.68 % | $ 15.9 B | USA |
 |
Profound Medical Corp.
PROF
|
3.92 M | $ 5.16 | -4.44 % | $ 180 M | Canada |
 |
Pulmonx Corporation
LUNG
|
23.4 M | $ 1.38 | -1.08 % | $ 56.1 M | USA |
 |
Quanterix Corporation
QTRX
|
73.9 M | $ 3.75 | -4.82 % | $ 160 M | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
InspireMD
NSPR
|
6.33 M | $ 1.79 | 3.47 % | $ 115 M | Israel |